MIOT
CBAY

Massachusetts Institute of Technology’s Cymabay Therapeutics CBAY Stock Holding History

Massachusetts Institute of Technology’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-38,894
Closed -$580K – 13
2023
Q3 		$580K Buy
+38,894
New +$516K 0.1% 7

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Massachusetts Institute of Technology's CBAY Position: Q4 2023 in Review

Massachusetts Institute of Technology sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 38,894 shares — an estimated $580K sold.

Massachusetts Institute of Technology first reported a position in CBAY in Q3 2023 and held it in 1 quarter. The position peaked at $580K in Q3 2023. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

  • Massachusetts Institute of Technology reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Massachusetts Institute of Technology sold 38,894 Cymabay Therapeutics shares in Q4 2023, an estimated $580K.
  • Massachusetts Institute of Technology first reported a position in Cymabay Therapeutics in Q3 2023 and held it in 1 quarter.
  • Massachusetts Institute of Technology's Cymabay Therapeutics position peaked at $580K in Q3 2023.
  • 200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Massachusetts Institute of Technology's 13F filing for Q4 2023, filed 13 Feb 2024.